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APOE-E4 is associated with memory
decline in cognitively impaired elderly
M.G. Dik, MSc; C. Jonker, MD, PhD; L.M. Bouter, PhD; M.I. Geerlings, MSc; G.J. van Kamp, PhD;
and D.J.H. Deeg, PhD
Article abstract—Objective: To investigate whether the association between APOE-e4 and memory decline is modified by
baseline cognition and age in a population-based elderly sample. Methods: The study sample consisted of 1,243 subjects,
62 to 85 years old, with a Mini-Mental State Examination (MMSE) score between 21 and 30 and known APOE pheno-
types. Memory performance was measured with an abbreviated Auditory Verbal Learning Test (AVLT) at baseline and
repeated after 3 years (n = 854). Memory decline was defined as a decrease of at least 1 SD from the mean change score on
immediate recall (IR), delayed recall (DR), and retention, based on the AVLT. Results: Multivariate logistic regression
analyses showed that APOE-e4 is associated with memory decline in cognitively impaired subjects (MMSE score, 21 to 26)
(OR for decline on IR adjusted for age, sex, education, and baseline recall score, 3.8; 95% CI, 1.4 to 10.0; adjusted OR for
decline on DR, 2.9; 95% CI, 1.2 to 7.0; adjusted OR for decline on retention, 3.3; 95% CI, 1.1 to 10.1), but not in cognitively
normal subjects (MMSE score, 27 to 30) (adjusted OR for decline on IR, 1.1; 95% CI, 0.6 to 2.0; adjusted OR for decline on
DR, 1.0; 95% CI, 0.6 to 1.8; adjusted OR for decline on retention, 1.5; 95% CI, 0.7 to 3.0). In particular, cognitively
impaired €4 carriers older than 75 years were at high risk of memory decline (adjusted OR for decline on IR, 4.5; 95% CI,
1.4 to 13.8; adjusted OR for decline on DR, 3.6; 95% CI, 1.2 to 10.8; adjusted OR for decline on retention, 6.6; 95% CI, 1.5
to 29.7). Conclusions: APOE-€4 was associated with memory decline in subjects with cognitive impairment, but not in
normally functioning subjects. Contrary to AD studies, our study suggests that the risk of APOE-e4 on memory decline
does not decrease at higher ages. Key words: APOE—Memory decline—AD—Age—Population-based study—Elderly.
NEUROLOGY 2000;54:1492-1497
The APOE-€4 allele has been established to be a risk
factor of late-onset AD. 1,2 However, studies suggest
that the E4-associated risk of incident AD decreases
after age 70. 3 5 Recently, studies have focused on in-
vestigating whether APOE-E4 can predict cognitive
decline and progression into AD. 6 8 Decline in mem-
ory, in particular in delayed recall, has been shown
to be one of the earliest indicators of dementia.6'9
Therefore, studies that investigate the association
between APOE-€4 and cognitive function focus on
memory decline.
There seems to be a modifying effect of baseline
cognition on the association between APOE-€4 and
memory decline, but the studies to date present in-
consistent results. A case-control study 1 " reported a
poorer memory performance among APOE-E4 carri-
ers with mild cognitive impairment at baseline com-
pared with non-E4 carriers. In subjects with baseline
normal cognition, however, APOE-€4 status was not
associated with poor memory performance. In con-
trast, a longitudinal community-based study" could
not demonstrate an association between APOE-E4
and memory decline in nondemented elderly with
baseline impaired cognition. Surprisingly, in subjects
with normal baseline cognition, APOE-E4 carriers
showed a greater memory decline compared to
non-E4 carriers.
Besides baseline cognitive function, differences in
age might explain the inconsistent findings. Studies
among subjects younger than 60 years did not ob-
serve an association between APOE-€4 and performance
on delayed recall or other cognitive measures. 12, " Most
community-based studies that did find an associa-
tion between the APOE-E4 allele and memory perfor-
mance used subjects aged 70 years and older. 2,14,16 In
contrast to AD studies, these findings suggest that
the risk of APOE-E4 on memory decline increases
with increasing age in nondemented elderly.
In the current study, we investigated whether the
risk of APOE-E4 on memory decline is modified by
baseline cognition. Furthermore, we explored the
role of age in the association between APOE-E4 and
memory decline. All subjects originated from a large
community sample of elderly, with a wide age range.
Methods. Sample description. Participants for the
study were obtained from the study sample of the Longitu-
dinal Aging Study Amsterdam (LASA), a multidisciplinary
study on changes in autonomy and well-being in the aging
population. 16 The LASA respondents were recruited from
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the municipal registries in the regions Amsterdam, Oss,
and Zwolle, resulting in 3,107 respondents aged 55 to 85
years. Both the oldest age groups and men were over-
represented, so that approximately equal numbers of men
and women in each age stratum (55 to 59, 60 to 64, 65 to
69, 70 to 74, 75 to 79, and 80 to 85 years) were obtained.
The sample and study design have been described in detail
elsewhere.' 7,18 Approval for the study was given by the
local medical ethics committee and all respondents gave
informed consent at the start of the study.
The study design involved blood collection and memory
testing in subjects aged 62 years and older (born in 1930 or
before) living in the Amsterdam and Zwolle region (n
1,551). APOE phenotype could be determined in 1,297 sub-
jects (83.6%). Subjects with a Mini-Mental State Examina-
tion (MMSE) score <21 were excluded because they were
suspected of dementia. This resulted in a baseline sample
of 1,243 subjects.
Follow-up measurement was completed for 876 subjects
(70.5% of 1,243) after an average of 3.1 (SD = 0.2) years of
follow-up. Loss to follow-up was caused by death (13.5%),
refusal (11.1%), ineligibility due to frailty (4.4%), and loss
of contact (0.5%). For 22 subjects no difference score on the
memory task could be calculated, because data were miss-
ing on either the first or the second measurement. This re-
sulted in 854 subjects with valid data on both measurements.
Measurements. Cognitive functioning. Cognitive func-
tion was measured with the MMSE at baseline. 19 Memory
was measured with an abbreviated version of the Auditory
Verbal Learning Test (AVLT). 2° We used three instead of
five learning trials to reduce the test burden for the re-
spondent. For each trial, the interviewer read aloud a list
of 15 words, after which the respondents summed up as
many words as they could remember. After an interval of
approximately 20 minutes, during which a different non-
verbal task was performed, the respondents were asked to
recall as many words as possible (delayed recall). We noted
the number of correctly recalled words (points). Words
mentioned by the respondent that were not on the AVLT
word list were not counted. Furthermore, words that were
mentioned more than once by the respondent were only
counted one time (each trial). Immediate recall (score on
the third trial, range 0 to 15), delayed recall (range 0 to
15), and memory retention (delayed recall/third trial X
100%) were analyzed. At follow-up, a parallel version of
the AVLT was used. The parallel versions, which are used
in treatment research, 2 ' were validated and tested for par-
allelism.22
APOE phenotype determination. Serum samples were
frozen at —80 °C until determination of APOE phenotype.
APOE phenotypes were determined by isoelectric focusing
of delipidated plasma samples, followed by immunoblot-
ting. 23 Participants were classified as E4 carriers for those
with an APOE-E4 isoform (phenotypes €214, €314, €414) and
as non-E4 carriers for those without an APOE-E4 isoform
(phenotypes E2/2, E2/3, €313).
Sample characteristics. At baseline, data on age and
sex were derived from the municipal registries. Educa-
tional level was assessed by asking the respondent for the
highest educational level completed, ranging from incom-
plete elementary education to university education. This
was converted into years of education (range, 5 to 18). To
obtain insight into the clinical characteristics of the study
sample, important for distinguishing cognitive impairment
from dementia, we described functional ability of the sub-
jects. As an indicator of functional ability, the respondents
were asked whether they received help with personal care.
Data analysis. The study sample was stratified into
subjects with normal cognition and subjects with cognitive
impairment. The baseline MMSE scores were used as an
external criterium, with MMSE scores 27 to 30 indicating
normal cognition and MMSE scores 21 to 26 indicating
impaired cognition. These cognition strata were further
divided by age (62 to 74 years and 75 to 85 years).
Between-strata differences in APOE status and sex
were tested with the x2 test. Differences in age, years of
education, MMSE, and memory test performance were
studied with the Student's t-test for independent samples.
Using the baseline data only, differences between E4 carri-
ers and non-E4 carriers in memory performance were
tested with the Student's t-test. Furthermore, multivariate
linear regression analyses were performed to detect an
effect of APOE-E4 on memory performance adjusted for age
(continuous variable), sex, and years of education.
The change in memory score was calculated for each
individual as the difference between the baseline score and
the follow-up score. Against the background of early devel-
opment of AD, we were interested in clinically relevant
memory decline, meaning memory decline that is substan-
tially greater than the mean decline of the study sample.
Therefore, decline in memory was defined as a decrease of
at least 1 SD from the mean change score. This resulted in
a decline of three or more points on immediate recall, a
decline of two or more points on delayed recall, and a
decline of 27% or more on retention of the AVLT. Differ-
ences in proportion of decline between E4 carriers and
non-e4 carriers were evaluated with the x 2 test. Multivari-
ate logistic regression analyses were performed to investi-
gate the association between APOE-E4 and memory decline
adjusted for age (continuous variable), sex, years of educa-
tion, and baseline recall score (i.e., baseline immediate
recall for decline on immediate recall, baseline delayed
recall for decline on delayed recall, baseline retention score
for decline on retention).
Because cut-off of the MMSE may be arbitrary, an in-
teraction term of APOE-E4 with the MMSE score as a
continuous variable was evaluated. Also, the interaction of
APOE-E4 and age was evaluated. Furthermore, MMSE
performance may be influenced by education and age. Be-
cause we wanted to explore the role of age in this study, it
was not appropriate to adjust the MMSE scores for age.
Therefore, MMSE scores adjusted for education were cal-
culated, whereas age effects were preserved. This was done
using a regression approach. 24 MMSE scores adjusted for
education were predicted within 5-year age strata. For
each subject a residual score was calculated as the ob-
served MMSE score minus the predicted score. The ad-
justed score was calculated by adding the mean score of
the age stratum to the residual score. These adjusted
scores were categorized in the MMSE strata 21 to 26 and
27 to 30 points, and multivariate logistic regression analy-
ses were performed. Also, we did the analyses in subjects
with MMSE scores of 24 to 26 points.
Results. The distribution of the APOE phenotypes was
in Hardy-Weinberg equilibrium. Loss to follow-up was as-
sociated with older age, lower education, and lower scores
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Characteristic MMSE 27-30, n = 866 MMSE 21-26, n = 377 p Value*
APOE €4 +, n (%) 213 (24.6) 107 (28.4) 0.16
APOE €4	 n (%) 653 (75.4) 270 (71.6)
Men, n (%) 440 (50.8) 193 (51.2) 0.90
Women, n (%) 426 (49.2) 184 (48.8)
Mean (SD) age, y 72.1 (6.5) 75.6 (6.6) <0.001
Mean (SD) education, y 9.2 (3.3) 7.7 (2.9) <0.001
MMSE, mean (SD) 28.4 (1.0) 24.6 (1.5) <0.001
Immediate recall, mean (SD) 7.8 (2.4) 5.9 (2.3) <0.001
Delayed recall, mean (SD) 5.2 (2.5) 3.4 (2.2) <0.001
Retention, mean (SD) 66.5 (27.9) 57.0 (31.4) <0.001
* p Values indicate level of significance by X 2 test or Student's t-test.
MMSE = Mini-Mental State Examination.
on all cognitive measures (all p < 0.001). More men were
lost to follow-up, although differences were not significant.
More importantly, loss to follow-up was not selective to
APOE-E4 frequency: 25.8% of E4 carriers completed follow-
up, compared with 25.7% of E4 carriers who were lost to
follow-up.
Of the 1,243 subjects in this study, at baseline 377
(30.3%) scored in the impaired range (21 to 26 points) and
866 (69.7%) scored in the normal range (27 to 30 points) of
the MMSE. Table 1 shows the baseline sample character-
istics for both subgroups. The groups did not differ signifi-
cantly in APOE status or sex. The cognitively impaired
subjects were on average older, less educated, and had
lower scores on all cognitive measures compared with the
cognitively normal subjects (all p < 0.001). Of the cogni-
tively impaired elderly, 93.9% did not receive help with
personal care, indicating that the large majority was not
impaired in functional ability.
Table 2 (upper part) shows the baseline characteristics
for cognitively normal and impaired subjects, separated for
subjects younger and older than 75 years. The proportion
of memory decline was generally highest in cognitively
impaired subjects older than 75 years (table 2, lower part).
Cross-sectional analyses of the association between
Table 2 Demographic characteristics, baseline cognition, and proportion of decline for subjects with normal cognition (MMSE 27-30)
and cognitive impairment (MMSE 21-26), by age
Table 1 Demographic characteristics and cognition at baseline for subjects with normal cognition (MMSE 27-30) and cognitive
impairment (MMSE 21-26)
Characteristic










n = 228 Value*
Cross-sectional
APOE €4 +, n (%)


















Women, n (%) 291 (51.6) 135 (44.7) 79 (53.0) 105 (46.1)
Mean (SD) age, y 68.0 (3.7) 79.5 (2.8) <0.001 68.4 (3.5) 80.2 (2.9) <0.001
Mean (SD) education, y 9.2 (3.1) 9.1 (3.7) 0.73 8.0 (2.9) 7.5 (3.0) 0.17
MMSE, mean (SD) 28.5 (1.0) 28.1 (1.0) <0.001 24.9 (1.3) 24.5 (1.6) <0.01
IR, mean (SD) 8.3 (2.4) 7.0 (2.3) <0.001 6.9 (2.3) 5.3 (2.1) <0.001
DR, mean (SD) 5.7 (2.5) 4.4 (2.3) <0.001 4.2 (2.2) 2.9 (2.1) <0.001
Ret, mean (SD) 68.7 (27.1) 62.5 (28.8) <0.01 61.5 (29.3) 53.9 (32.4) 0.02
Longitudinal
Decline in IR, n (%) 40 (8.8) 18 (9.9) 0.65 6 (5.9) 20 (16.9) 0.01
Decline in DR, n (%) 56 (12.3) 33 (18.2) 0.05 10 (9.9) 23 (19.5) 0.05
Decline in Ret, n (%) 33 (7.3) 25 (13.8) 0.01 12 (11.9) 14 (12.4) 0.91
* p Values indicate level of significance by X 2 test or Student's t-test.
MMSE = Mini-Mental State Examination; IR = immediate recall; DR = delayed recall; Ret = retention.
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Table 3 Baseline memory function and proportion of decline for subjects with normal cognition (MMSE 27-30) and cognitive
impairment (MMSE 21-26) in two age groups, by APOE status
Characteristic











APOE-e4 + 8.4 (2.5) 7.6 (2.4)* 6.4 (2.1) 4.9 (2.1)*
APOE-€4 - 8.2 (2.3) 6.9 (2.3) 7.1 (2.3) 5.5 (2.0)
DR, mean (SD)
APOE-€4 + 5.8 (2.6) 4.7 (2.5) 3.7 (2.2) 2.5 (1.9)*
APOE-€4 - 5.6 (2.5) 4.3 (2.3) 4.4 (2.2) 3.1 (2.0)
Ret, mean (SD)
APOE-e4 + 70.5 (32.0) 60.7 (31.4) 59.6 (36.1) 50.2 (36.6)
APOE-e4 - 67.9 (25.0) 62.9 (28.3) 62.3 (26.2) 55.3 (30.7)
Longitudinal
Decline in IR, n (%)
APOE-€4 + 11 (9.0) 5 (13.5) 2 (7.1) 10 (30.3)*
APOE-e4 - 29 (8.7) 13 (9.0) 4 (5.5) 10 (11.8)
Decline in DR, n (%)
APOE-€4 + 18 (14.8) 6 (16.2) 3 (10.7) 10 (30.3)
APOE-e4 - 38 (11.4) 27 (18.8) 7 (9.6) 13 (15.3)
Decline in ret, n (%)
APOE-e4 + 14 (11.5)* 4 (10.8) 4 (14.3) 7 (22.6)*
APOE-e4 - 19 (5.7) 21 (14.6) 8 (11.0) 7 (8.5)
* Significant differences (p 0.05) between €4 carriers (€4 +) and noncarriers (€4 -) evaluated with Student's t-test or x 2 test.
MMSE = Mini-Mental State Examination; IR = immediate recall; DR = delayed recall; Ret = retention.
APOE-E4 and memory function did not show differences in
memory function between E4 carriers and non-E4 carriers
for both cognitively normal and cognitively impaired sub-
jects younger than 75 years (table 3, upper part). Cogni-
tively normal APOE-E4 carriers 75 years scored higher
on immediate recall ( p = 0.03) than cognitively normal
non-E4 carriers  75 years; no differences were found for
delayed recall performance and retention. Cognitively im-
paired E4 carriers  75 years scored significantly lower on
both immediate and delayed recall-not on retention-
than cognitively impaired non-E4 carriers  75 years. The
differences remained significant after adjustment for age
(continuous variable), sex, and education in linear regres-
sion analyses (data not shown). The proportion of decline
on immediate recall and retention was significantly higher
among cognitively impaired E4 carriers  75 years as com-
pared to non-E4 carriers. Furthermore, the proportion of
decline on retention was slightly but significantly higher
among the youngest cognitively normal E4 carriers as com-
pared to the non-E4 carriers (table 3, lower part).
Logistic regression analyses adjusted for age, sex, edu-
cation, and baseline recall score showed an association
between APOE-E4 and memory decline only in cognitively
impaired subjects (OR = 3.8, 95% CI, 1.4 to 10.0 for imme-
diate recall; OR = 2.9, 95% CI, 1.2 to 7.0 for delayed recall;
OR = 3.3, 95% CI, 1.1 to 10.1 for retention), but not in
cognitively normal subjects (OR = 1.1, 95% CI, 0.6 to 2.0 for
immediate recall; OR = 1.0, 95% CI, 0.6 to 1.8 for delayed
recall; OR = 1.5, 95% CI, 0.7 to 3.0 for retention) (table 4).
The interaction term of APOE-E4 with the continuous MMSE
score was significant for all memory measures. Analysis
within cognition strata based on education-adjusted MMSE
scores showed similar results to unadjusted MMSE strata
(data not shown). Furthermore, defining cognitive impair-
ment as MMSE scores of 24 to 26 did not change the results
(data not shown).
Age did not appear to be a significant modifier of the
association between APOE-E4 and memory decline. Sepa-
rate analyses in the two age strata showed, however, that
the relative risk of decline for cognitively impaired E4 car-
riers was particularly high in subjects older than 75 years
(OR = 4.5, 95% CI, 1.4 to 13.8 for immediate recall; OR =
3.6, 95% CI, 1.2 to 10.8 for delayed recall; OR = 6.6, 95%
CI, 1.5 to 29.7 for retention) (see table 4). When the cogni-
tion strata were based on education-adjusted MMSE
scores, the E4-related risk of memory decline in cognitively
impaired elderly  75 years was weakened, but not lower
than in subjects <75 years (<75 years: OR = 3.7, 95% CI,
0.8 to 17.2 for immediate recall; OR = 2.2, 95% CI, 0.5 to
8.8 for delayed recall; OR = 2.1, 95% CI, 0.5 to 9.9 for
retention;  75 years: OR = 3.2, 95% CI, 1.2 to 8.3 for
immediate recall; OR = 2.2, 95% CI, 0.9 to 5.6 for delayed
recall; OR = 2.5, 95% CI, 0.8 to 8.1 for retention). The
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Table 4 Association between APOE €4 and memory decline for
subjects with normal cognition (MMSE 27-30) and cognitive






Immediate 1.1 (0.6-2.0) 3.8 (1.4-10.0)
Age <75 y 1.0 (0.5-2.1) 2.9 (0.4-23.4)
Age  75 y 1.3 (0.4-4.0) 4.5 (1.4-13.8)
Delayed 1.0 (0.6-1.8) 2.9 (1.2-7.0)
Age <75 y 1.1 (0.6-2.2) 2.1 (0.4-10.8)
Age  75 y 0.9 (0.3-2.4) 3.6 (1.2-10.8)
Retention 1.5 (0.7-3.0) 3.3 (1.1-10.1)
Age <75 y 1.8 (0.8-4.4) 1.3 (0.2-8.3)
Age  75 y 1.0 (0.3-3.6) 6.6 (1.5-29.7)
Values expressed as OR (95% CI) adjusted for age (continuous
variable), sex, education, and baseline recall score (i.e., baseline
immediate recall for decline on immediate recall; baseline de-
layed recall for decline on delayed recall; baseline retention for
decline on retention).
MMSE = Mini-Mental State Examination.
results did not change when APOE-E2/4 carriers were ex-
cluded from the analyses.
Discussion. The aim of this study was to investi-
gate whether baseline cognition modifies the associa-
tion between APOE-€4 and memory decline. The
results show that APOE-e4 is a risk factor of memory
decline only in cognitively impaired and not in cogni-
tively normal subjects. These results are in line with
other studies."° In a selected sample of patients
with mild cognitive impairment, a higher crossover
to dementia was reported among APOE-€4 carriers
compared with non-€4 carriers. 9 In another study,
APOE-€4 was associated with poorer baseline mem-
ory performance in subjects with mild cognitive im-
pairment, but not in normal control subjects.1°
In contrast, the longitudinal community-based
Amsterdam Study of the Elderly (AMSTEL)" found
APOE-e4 associated with memory decline in cogni-
tively normal but not in impaired elderly. However,
based on the mean MMSE scores, the cognitively
normal elderly in AMSTEL were more comparable
with the cognitively impaired in our study. More-
over, the mean MMSE scores of the so-called mini-
mal dementia subgroup in AMSTEL were lower
compared with our impaired sample. Probably more
subjects in early stages of AD were included in the
minimal dementia sample of AMSTEL.
In our study, elderly scoring between 21 and 26 on
the MMSE were considered to be cognitively im-
paired. This range may include a heterogeneous
group of people who are normal, mildly impaired, or
actually demented. However, because the majority of
cases did not have an associated decline in their
functional ability, any truly demented subjects were
not included. 25 Furthermore, elevating the MMSE
lower cut-off from 21 to 24 to exclude demented sub-
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jects with more certainty did not change the results.
Also, the similar results that were found for
education-adjusted cognition strata and the signifi-
cant interaction of APOE-e4 with the continuous
MMSE score support the findings.
Our data further suggest that the €4-related risk
of memory decline in cognitively impaired subjects is
particularly high in those older than 75 years, com-
pared with the younger age stratum. Adjustments
for education weakened the risk in those 75 years
old, but the risk was still not lower than in those
<75 years old. These results are surprising and in
contrast with studies concerning the effect of age on
the risk of AD associated with APOE-e4.4,5,26-28 Stud-
ies on AD report a lower APOE-€4 allele frequency in
older age groups, 29 suggesting selective survival by
APOE status. In our study, the frequency of €4 was
not lower in cognitively impaired subjects older than
75 years, suggesting no selective attrition. This
might explain the effect of €4 on memory decline at
higher ages in our study.
One of the strengths of this study is that we used
data from a large longitudinal population-based
study so that we could distinguish cognitively nor-
mal and impaired subjects from the same source pop-
ulation. Second, we used memory measures that are
sensitive for early signs of Alzheimer-type demen-
tia. 6 ' 9 Moreover, these measures do not suffer from a
ceiling effect, which would limit the capacity to de-
tect decline in relatively well-functioning subjects,
especially those with a high level of education. Fi-
nally, the wide age range of our study population
made it possible to study the association between
APOE-€4 and memory decline both in subjects
younger and older than 75 years.
A limitation of our study is that our stringent
definition of memory decline resulted in rather small
numbers of cases, in particular in the youngest cog-
nitively impaired subgroup. We could not detect an
association between APOE-€4 and memory decline in
this subgroup, possibly because of insufficient power.
Nevertheless, in the oldest cognitively impaired sub-
group we found an association between APOE-€4 and
memory decline.
Our study showed that the association between
APOE-€4 and memory decline was modified by base-
line cognition. Only cognitively impaired APOE-€4
carriers were at higher risk of memory decline com-
pared with non-e4 carriers, in particular those €4
carriers who were older than 75 years. Contrary to
AD studies, our study suggests that the effect of
APOE-€4 on memory decline does not decrease at
higher ages. This finding raises the question
whether subjects who show memory decline at older
ages are at high risk for developing AD. It became
clear from many studies that contributing factors
other than APOE-€4 are necessary to develop AD. 5 The
important role of APOE-€4 on memory decline at ad-
vanced age in this study suggests that enrichment with
APOE-E4 does not imply, in itself, development of AD.
Acknowledgment
The authors are grateful to the Immunochemisch Laboratorium of
the Vrije Universiteit, Amsterdam, for APOE phenotyping. The
authors also thank Piet Eikelenboom, MD, PhD, for his comments
on an earlier draft of this article.
References
Strittmatter WJ, Saunders AM, Schmechel D, et al. Apoli-
poprotein E: high-avidity binding to beta-amyloid and in-
creased frequency of type 4 allele in late-onset familial
Alzheimer disease. Proc Natl Acad Sci USA 1993;90:1977-
1981.
Henderson AS, Easteal S, Jorm AF, et al. Apolipoprotein E
allele epsilon 4, dementia, and cognitive decline in a popula-
tion sample. Lancet 1995;346:1387-1390.
Evans DA, Beckett LA, Field TS, et al. Apolipoprotein E epsi-
lon4 and incidence of Alzheimer disease in a community pop-
ulation of older persons. JAMA 1997;277:822-824.
Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex,
and ethnicity on the association between apolipoprotein E ge-
notype and Alzheimer disease: a meta-analysis. APOE and
Alzheimer Disease Meta Analysis Consortium. JAMA 1997;
278:1349-1356.
Slooter AJ, Cruts M, Kalmijn 5, et al. Risk estimates of de-
mentia by apolipoprotein E genotypes from a population-based
incidence study: the Rotterdam Study. Arch Neurol 1998;55:
964-968.
Bondi MW, Salmon DP, Galasko D, Thomas RG, Thal
LJ. Neuropsychological function and apolipoprotein E geno-
type in the preclinical detection of Alzheimer's disease. Psy-
chol Aging 1999;14:295-303.
Caselli RJ, Graff-Radford NR, Reiman EM, et al. Preclinical
memory decline in cognitively normal apolipoprotein E-epsilon
4 homozygotes. Neurology 1999;53:201-207.
Staehelin HB, Perrig-Chiello P, Mitrache C, Miserez AR, Per-
rig WJ. Apolipoprotein E genotypes and cognitive functions in
healthy elderly persons. Acta Neurol Scand 1999;100:53-60.
Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E
status as a predictor of the development of Alzheimer's dis-
ease in memory-impaired individuals. JAMA 1995;273:1274-
1278.
Smith GE, Bohac DL, Waring SC, et al. Apolipoprotein E
genotype influences cognitive 'phenotype' in patients with Alz-
heimer's disease but not in healthy control subjects. Neurol-
ogy 1998;50:355-362.
Jonker C, Schmand B, Lindeboom J, Havekes LM, Launer L.
Association between apolipoprotein E epsilon4 and the rate of
cognitive decline in community-dwelling elderly individuals
with and without dementia. Arch Neurol 1998;55:1065-1069.
Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E
type 4 allele and cerebral glucose metabolism in relatives at
risk for familial Alzheimer disease. JAMA 1995;273:942-947.
13. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of
Alzheimer's disease in persons homozygous for the epsilon 4
allele for apolipoprotein E. N Engl J Med 1996;334:752-758.
Bondi MW, Salmon DP, Monsch AU, et al. Episodic memory
changes are associated with the APOE-epsilon 4 allele in non-
demented older adults. Neurology 1995;45:2203-2206.
Helkala EL, Koivisto K, Hanninen T, et al. The association of
apolipoprotein E polymorphism with memory: a population
based study. Neurosci Lett 1995;191:141-144.
Deeg DJH, Knipscheer CPM, van Tilburg W, eds. Autonomy
and well-being in the aging population: concepts and design of
the Longitudinal Aging Study Amsterdam. Bunnik: Nether-
lands Institute of Gerontology, 1993.
van den Heuvel N, Smits CHM, Deeg DJH, Beekman ATF.
Personality: a moderator of the relation between cognitive
functioning and depression in adults aged 55-85? J Affect
Disord 1996;41:229-240.
Smit JH, de Vries MZ, Poppelaars JL. Data-collection and
fieldwork procedures. In: Deeg DJH, Beekman ATF, Kriegs-
man DMW, Westendorp-de Seriere M, eds. Autonomy and
well-being in the aging population: volume II. Amsterdam: VU
University Press, 1998:9-20.
Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State":
A practical method for grading the cognitive state of patients
for the clinician. J Psychiatr Res 1975;12:189-198.
Rey A. L' examen clinique en psychologie. Paris: Presses Uni-
versitaire de France, 1964.
Moller JT, Cluitmans P, Rasmussen LS, et al. Long-term post-
operative cognitive dysfunction in the elderly: ISPOCD1
study. Lancet 1998;351:857-861.
Jolles J, Houx PJ, van Boxtel MPJ, Ponds RWHM, eds. Maas-
tricht Aging Study. Determinants of cognitive aging. Maas-
tricht: Neuropsych Publishers, 1995.
Havekes LM, de Knijff P, Beisiegel U, Havinga J, Smit M,
Klasen E. A rapid micromethod for apolipoprotein E pheno-
typing directly in serum. J Lipid Res 1987;28:455-463.
Kittner SJ, White LR, Farmer ME, et al. Methodological is-
sues in screening for dementia: the problem of education ad-
justment. J Chron Dis 1986;39:163-170.
Stern Y, Andrews H, Pittman J, et al. Diagnosis of dementia
in a heterogeneous population. Development of a neuropsy-
chological paradigm-based diagnosis of dementia and quanti-
fied correction for the effects of education. Arch Neurol 1992;
49:453-460.
Bickeboller H, Campion D, Brice A, et al. Apolipoprotein E
and Alzheimer disease: genotype-specific risks by age and sex.
Am J Hum Genet 1997;60:439-446.
Frisoni GB, Manfredi M, Geroldi C, et al. The prevalence of
apoE-epsilon4 in Alzheimer's disease is age dependent. J Neu-
rol Neurosurg Psychiatry 1998;65:103-106.
Breitner JCS, Wyse BW, Anthony JC, et al. APOE-epsilon 4
count predicts age when prevalence of AD increases, then
declines-The Cache County Study. Neurology 1999;53:321-
331.
Growdon JH, Locascio JJ, Corkin S, Gomez-Isla T, Hyman B.
Apolipoprotein E genotype does not influence rates of cogni-
tive decline in Alzheimer's disease. Neurology 1996;47:444-
448.
April (1 of 2) 2000 NEUROLOGY 54 1497
